Bristol Myers Squibb Reports Ten-Year CheckMate-067 Data for Opdivo Plus Yervoy in Melanoma

Bristol Myers Squibb today presented ten-year overall survival data from the Phase 3 CheckMate-067 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone or Yervoy alone in patients with previously untreated advanced melanoma. The data showed that 43% of patients in the Opdivo plus Yervoy arm were alive at ten years.